Germany Suspends Takeda Diabetes Drug Actos

Law360, New York (June 10, 2011, 5:42 PM EDT) -- German health regulators on Friday advised doctors to halt new prescriptions of Takeda Pharmaceutical Co. Ltd.'s diabetes drug Actos in light of study results suggesting the medication could heighten the risk of bladder cancer.

The announcement from Germany's Federal Institute for Drugs and Medical Devices follows France's decision Thursday to suspend use of drugs containing pioglitazone, based on testing in that country showing increased bladder cancer risks.

That suspension includes Takeda's Competact-brand drug, which is a combination of pioglitazone and metformin. Both Actos and Competact are...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.